Open an account

STAAR Surgical

STAA · NASDAQ

$22.32+$0.44 (+2.01%)TodayMarket closed ·
Prev close $21.88

About STAA

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Employees
957
Headquarters
Monrovia California, California
Listed
Feb 24, 1992
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
staar.com

STAA key statistics

Market cap
1.12B
Price-earnings ratio
273.50
Dividend yield
—
Average volume
754.34K
Volume
614.61K
Open price
$21.90
High today
$22.57
Low today
$21.85
52 Week high
$35.87
52 Week low
$15.59

STAAR Surgical (STAA) at a glance

STAAR Surgical (STAA) last traded at $22.32, with a market cap of 1.12B and a price-to-earnings ratio of 273.50.

Today the stock has traded between $21.85 and $22.57. The current price is 2.2% above the day's low and 1.1% below its high.

Volume so far is 614.61K shares, in line with the average of 754.34K shares a day.

Over the past year STAAR Surgical has ranged from $15.59 to $35.87, and now sits 33% of the way up that range.

STAAR Surgical met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.16 per share against an estimate of $0.1623.

The average analyst price target is $28.25, 26.6% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 8 analyst ratings say Buy
  • Buy50.0%
  • Hold37.5%
  • Sell12.5%
Price target · 12 analystsAvg $28.25
Low
$19.19
Now
$22.32
High
$38.85

STAA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 129.2% on average.

  1. Q3 FY24: reported $0.38 per share against an estimate of $0.1724
  2. Q4 FY24: reported -$0.50 per share against an estimate of $0.0152
  3. Q1 FY25: reported -$0.53 per share against an estimate of -$0.6066
  4. Q2 FY25: reported -$0.34 per share against an estimate of -$0.6743
  5. Q3 FY25: reported $0.18 per share against an estimate of $0.1647
  6. Q4 FY25: reported -$0.37 per share against an estimate of $0.0583
  7. Q1 FY26: reported $0.23 per share against an estimate of -$0.065
  8. Q2 FY26: reported $0.16 per share against an estimate of $0.1623

STAA news

  • Press releaseBusiness Wire

    STAAR Surgical Names Andrew Pilon as Vice President of Business Development

  • Priya Nigam

    STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside

  • Press releaseBusiness Wire

    STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).

  • Press releaseBusiness Wire

    STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

  • Press releaseBusiness Wire

    STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

  • Press releaseBusiness Wire

    STAAR Surgical Reports Second Quarter 2026 Results

  • Press releaseBusiness Wire

    STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

Similar companies

Companies in the same industry as STAAR Surgical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.